NASDAQ:SVA

SINOVAC Reports Unaudited Second Half of 2023 Financial Results and Files 2023 Annual Report on Form 20-F

Retrieved on: 
Monday, April 29, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Heng, NMPA, The Twelve Months, Vaccine, Enterovirus, District court, Court, GAAP, Person, EV71, WHO, Hearing, National Medical Products Administration, Hand, Exchange, Complaint, Sinovac Biotech, Privy council, Good, Annual report, Influenza, Infection, OrbiMed, Motion, Foot, Judgement, Rights, GMP, Clinical trial, Government, Appellate court, Medication, Capital, Ageing, Influenza vaccine, Cancer, Trust, Bank statement, HFMD, COVID-19, Growth, Hepatitis

The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.

Key Points: 
  • The Company also reported its unaudited financial results for the second half and audited financial for the full year ended December 31, 2023.
  • Sales for the second half of 2023 were $307.9 million, compared to $280.5 million in the prior year period.
  • R&D expenses in the second half of 2023 were $193.4 million, compared to $257.7 million in the prior year period.
  • The Company’s financial statements for the second half of 2023 are prepared and presented in accordance with U.S. GAAP.

Sinovac Amends Shareholder Rights Plan

Retrieved on: 
Wednesday, February 21, 2024
Health, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, Sinovac Biotech

Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.

Key Points: 
  • Sinovac Biotech Ltd. (“Sinovac” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that its board of directors has amended its shareholder rights plan.
  • The amendment extends the expiration date of the plan from February 22, 2024 to February 22, 2025.

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Retrieved on: 
Thursday, January 18, 2024
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Agreement, Tender offer, Rights, Schedule, Sale, Investment, Shareholder, Tender, Expiration, NOT, Alternative, Liquidity, Cryptocurrency

Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.

Key Points: 
  • Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.
  • The Tender Offer was reviewed and considered by the Board of Directors, none of whom are affiliated with Alternative Liquidity.
  • The Board of Directors took into account various factors in evaluating the Tender Offer and in support of its recommendation that the Shareholders reject the Tender Offer and not tender their shares in the Tender Offer, including the following.
  • The Board of Directors’ belief in this regard is supported by Alternative Liquidity’s own characterization of the Tender Offer.

SINOVAC Reports on the Clinical Trial Progress of its Anti-COVID-19 Antibody SA55 Injection

Retrieved on: 
Monday, September 11, 2023
COVID-19, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Other Science, Science, Vaccine, Contraindication, Vaccination, University of the Chinese Academy of Sciences, Half-life, SARS-CoV-2, Infection, Clinical trial, SARS, Chinese Academy of Medical Sciences COVID-19 vaccine, Sinovac Biotech, Patient, Blood, Ageing, Immunodeficiency, Safety, Pharmaceutical industry

Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.

Key Points: 
  • Sinovac Biotech Ltd. (“SINOVAC” or the “Company”) (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced that the Company has completed the phase I clinical trial for its broad-spectrum neutralizing antibody product, the Anti-COVID-19 Antibody SA55 Injection (“SA55 Injection”) in Beijing and has entered the phase II clinical trial in Shanghai after successfully enrolling its first participant recently.
  • SINOVAC’s SA55 Injection, which is intended for the treatment of COVID-19 infections, was approved for clinical trial in China on May 24, 2023.
  • The phase I clinical trial has confirmed its preliminary safety profile in 40 healthy adults aged 18 to 65 in China.
  • China’s National Medical Products Administration has approved SINOVAC’s SA55 Nasal Spray for clinical trial in the prevention of COVID-19 infections, in April 2023.

Sinovac Board of Directors Unanimously Rejects an Unsolicited Partial Tender Offer

Retrieved on: 
Tuesday, September 5, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, Agreement, Liquidity, Shareholder, NOT, Independent Monitoring Authority for the Citizens' Rights Agreements, Tender offer, Financial assistance (share purchase), Expiration date, Rights, Securities and Exchange Commission (Nigeria), Sale, Schedule, Tender, Expiration, Investment, Alternative, Cryptocurrency, Management, Sinovac Biotech, Purchasing, Share (finance)

Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.

Key Points: 
  • Accordingly, the Board of Directors recommends that the Shareholders reject the Tender Offer and not tender their Shares for purchase pursuant to the Offer to Purchase by Alternative Liquidity.
  • The Tender Offer was reviewed and considered by the Board of Directors, none of whom are affiliated with Alternative Liquidity.
  • The Board of Directors took into account various factors in evaluating the Tender Offer and in support of its recommendation that the Shareholders reject the Tender Offer and not tender their shares in the Tender Offer, including the following.
  • The Board of Directors’ belief in this regard is supported by Alternative Liquidity’s own characterization of the Tender Offer.

Sinovac Confirms Receipt of an Unsolicited Partial Tender Offer

Retrieved on: 
Tuesday, August 29, 2023
Infectious Diseases, Biotechnology, Pharmaceutical, Health, Sinovac Biotech, Alternative, Cryptocurrency, Management

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.

Key Points: 
  • Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, confirmed today that it is aware of an unsolicited partial tender offer from Alternative Liquidity Index LP to purchase up to a maximum of 10,000,000 shares of the Company, representing approximately 10.05% of the Company’s outstanding shares, for $0.03 per share in cash.
  • Sinovac’s Board of Directors intends to evaluate the terms of the tender offer to determine the course of action that it believes is in the best interest of the Company and its shareholders.
  • The Board also intends to advise shareholders of the Board’s position regarding the tender offer within ten business days of receipt of the offer.
  • In the meantime, the Company’s shareholders are strongly advised to take no action in relation to the tender offer.

Sinovac Announces Change of Legal Representative of Sinovac Beijing

Retrieved on: 
Monday, August 28, 2023
Science, Legal, Biotechnology, Research, Pharmaceutical, Health, Infectious Diseases, Professional Services, Verdict, Administration, Civil Mediation Council, Assistance, Consent, Fine chemical, Automotive industry, Sinovac Biotech

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“Sinovac Beijing”), has changed its legal representative to Mr. Weidong Yin, the Company’s Chairman, President and Chief Executive Officer.

Key Points: 
  • Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today that the Company’s subsidiary, Sinovac Biotech Co., Ltd. (“Sinovac Beijing”), has changed its legal representative to Mr. Weidong Yin, the Company’s Chairman, President and Chief Executive Officer.
  • The Administration for Market Regulation Bureau of Beijing Haidian District notified Sinovac Beijing that the minority shareholder and the legal representative of Sinovac Beijing have been changed in accordance with the Notice of Assistance of Court Verdict Execution, the Verdict Execution Order and the Consent Judgement on the Civil Mediation Agreement by Shandong Province Zibo City Zhangdian District People’s Court.
  • Mr. Weidong Yin has been appointed the legal representative and chairman of the board of directors of Sinovac Beijing.
  • The Administration for Market Regulation Bureau of Beijing Haidian District issued an updated business license dated August 25, 2023 to Sinovac Beijing.

SINOVAC Reports Unaudited First Half of 2023 Financial Results

Retrieved on: 
Tuesday, August 15, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology

Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023.

Key Points: 
  • Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023.
  • SINOVAC’s influenza vaccines expand international market accessibility in the first half of 2023 by gaining more overseas market approvals, such as Pakistan and Chile.
  • Sales for the first half of 2023 were $140.4 million, compared to $1.2 billion in the prior year period.
  • The Company’s first half of 2023 financial statements are prepared and presented in accordance with U.S. GAAP.

SINOVAC’s CoronaVac® Answers Hong Kong’s Need for Self-Pay COVID-19 Vaccines

Retrieved on: 
Wednesday, May 10, 2023
Health, Infectious Diseases, COVID-19, General Health, Pharmaceutical, Biotechnology, Vaccine, Infection, University, Vaccination, Immunization, Public, Parent, Sinovac Biotech, Hospital, COVID, Omicron, Multisystem inflammatory syndrome, Government, Organization, Death, Amnesia, Insomnia, Patient, Risk, Ageing, ICU, Safety, Disease, Pharmaceutical industry

Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect against COVID-19.

Key Points: 
  • Additionally, the company will collaborate with local charity groups to provide donations, giving more children in Hong Kong access to free vaccines to protect against COVID-19.
  • “SINOVAC’s ongoing fight against COVID-19 is based on our mission to ‘supply vaccines to eliminate human diseases,’” said Yin Weidong, Chairman, President, and CEO of SINOVAC.
  • Hospitalization and the long-term effects of COVID-19 can be serious, particularly among children, underscoring the need for accessible and affordable vaccinations and boosters.
  • SINOVAC is addressing these concerns by supplying the private market in Hong Kong with their inactivated COVID-19 vaccine, thus offering a viable solution for these patients.

SINOVAC Reports Unaudited Second Half of 2022 Financial Results and Files 2022 Annual Report on Form 20-F

Retrieved on: 
Monday, May 1, 2023
Health, Infectious Diseases, Research, Pharmaceutical, Science, Biotechnology

The Company also reported its unaudited financial for the second half and audited financial for full year ended December 31, 2022.

Key Points: 
  • The Company also reported its unaudited financial for the second half and audited financial for full year ended December 31, 2022.
  • Sales for the second half of 2022 were $280.5 million, compared to $8.4 billion in the prior year period.
  • R&D expenses in the second half of 2022 were $257.7 million, compared to $101.1 million in the prior year period.
  • The Company’s second half of 2022 financial statements are prepared and presented in accordance with U.S. GAAP.